Regulus Therapeutics Inc expected to post a loss of 48  cents a share - Earnings Preview

Regulus Therapeutics

09/08/2022 21:55

* Regulus Therapeutics Inc  RGLS.OQ   RGLS.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 11. 
    * ​Refinitiv's mean analyst estimate for Regulus
Therapeutics Inc
is for a loss of 48 cents per share. For the same quarter last
year, the company reported a loss of 80 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $20​, above​ its last closing price
of $1.77. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.56       -0.53      -0.50     Beat    6.2
 Dec. 31 2022  -0.62       -0.67      -0.70     Missed  -5
 Sep. 30 2021  -0.76       -0.77      -1.00     Missed  -29​
 Jun. 30 2021  -0.80       -0.80      -0.80     Met     0
 ​​Mar.        -0.90       -0.90      -0.80     Beat    11.1
 31 2021                                                
 Dec. 31 2020  -1.00       -1.40      -0.30     Beat    78.6​
 Sep. 30 2020  -2.17       -2.07      -0.40     Beat    80.7
 Jun. 30 2020  -0.77       -1.07      -2.30     Missed  -114
 This summary was machine generated August 9 at 20:55 GMT.  All
figures in US dollars  unless otherwise stated